Table 4.
RMT-based nanomaterial drug delivery system.
| Drug Carrier | Ligand | Receptor |
|---|---|---|
| Human serum albumin nanoparticles [115] | Transferrin (Tf)/ transferrin receptor monoclonal antibodies (OX26 or R17217) | Transferrin receptor |
| Pegylated liposome [116] | Transferrin (Tf) | |
| Poly-(lactide-co-glycolide) (PLGA) [117] | ||
| PLGA [118] | Mouse monoclonal antibody against the transferrin receptor (8D3) | |
| Polyethylene glycol (PEG)-coated Fe3O4 [119] | Lactoferrin (Lf) | Lf receptor |
| Nanoliposomes [114] | Apolipoprotein E (ApoE)-derived peptides | Low-density lipoprotein receptor |
| Pluronic-based nano-carrier [106] | Rabies virus glycoprotein | g-aminobutyric acid (GABA) /nicotinic acetylcholine (nACh) receptor |
| Poly(ethylenimine) [35] | ||
| Porous silica nanoparticle [120] | RGD (arginine–glycine–aspartate) peptide | αvβ3 and αvβ5 integrins |
| Glial-derived neurotrophic factor [121] | Chimeric monoclonal antibody | Insulin receptor |
| Human serum albumin (HSA) nanoparticles [122] | Anti-insulin receptor monoclonal antibody (29B4) |